CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 63 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $17,474,836 | +106.2% | 588,378 | +25.0% | 0.01% | +120.0% |
Q2 2023 | $8,475,606 | +26.7% | 470,736 | +13.1% | 0.01% | +25.0% |
Q1 2023 | $6,687,087 | -10.0% | 416,252 | +2.5% | 0.00% | -20.0% |
Q4 2022 | $7,428,542 | +98.9% | 406,264 | +7.0% | 0.01% | +66.7% |
Q3 2022 | $3,735,732 | -48.3% | 379,696 | -22.8% | 0.00% | -40.0% |
Q1 2020 | $7,228,000 | -41.1% | 491,691 | +0.6% | 0.01% | -16.7% |
Q4 2019 | $12,266,000 | +64.2% | 488,872 | -1.6% | 0.01% | +50.0% |
Q3 2019 | $7,470,000 | -40.2% | 496,660 | -0.6% | 0.00% | -42.9% |
Q2 2019 | $12,489,000 | +12.4% | 499,542 | +2.3% | 0.01% | +16.7% |
Q1 2019 | $11,115,000 | -30.0% | 488,367 | -7.8% | 0.01% | -40.0% |
Q4 2018 | $15,889,000 | +5.7% | 529,826 | +1.0% | 0.01% | +25.0% |
Q3 2018 | $15,034,000 | – | 524,744 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 2,030,616 | $31,028,000 | 6.04% |
5AM Venture Management, LLC | 1,362,286 | $20,816,000 | 3.75% |
Burrage Capital Management LLC | 272,393 | $4,162,000 | 3.37% |
Altium Capital Management LP | 361,930 | $5,530,000 | 1.54% |
Vivo Capital, LLC | 2,214,138 | $33,832,000 | 1.19% |
Bain Capital Life Sciences Investors, LLC | 1,071,428 | $16,371,000 | 0.93% |
Perceptive Advisors | 3,659,381 | $51,606,000 | 0.65% |
New Leaf Venture Partners, L.L.C. | 141,000 | $2,154,000 | 0.50% |
DRIEHAUS CAPITAL MANAGEMENT LLC | 2,003,688 | $30,616,000 | 0.45% |
Opaleye Management Inc. | 188,000 | $2,873,000 | 0.42% |